Medicine used for treating genetic imprinting subtype hemangioblastoma

A technology of hemangioblastoma and gene imprinting, which is applied in drug combinations, antineoplastic drugs, and pharmaceutical formulations, can solve the problems of ineffective treatment of gene imprinted subtype hemangioblastoma, and achieve good therapeutic and preventive effects

Inactive Publication Date: 2019-08-02
AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] In the prior art, the main drug for the treatment of hemangioblastoma is aimed at hemangioblastoma caused by VHL gene mutation, and these drugs cannot effectively treat gene imprinted subtype hemangioblastoma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine used for treating genetic imprinting subtype hemangioblastoma
  • Medicine used for treating genetic imprinting subtype hemangioblastoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0014] In order to make the technical means, creative features, goals and effects of the present invention easy to understand, the following examples will specifically illustrate the drug for the treatment of gene imprinted subtype hemangioblastoma of the present invention in conjunction with the accompanying drawings.

[0015] In this example, three hemangioblastoma brain tumor patients (a mother and her two sons) in a family and relatives in the family were used as research objects, and the peripheral blood of the research objects and three brain tumor patients were collected. Paraffin sections of tumor tissues resected from patients (abbreviated as HB samples) were used for experiments. The collection of samples from these patients and their relatives was approved by the Ethics Committee of Huashan Hospital of Fudan University, and they signed informed consent forms with themselves.

[0016] The experimental methods in this example are all conventional experimental methods,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a medicine used for treating genetic imprinting subtype hemangioblastoma. The medicine used for treating genetic imprinting subtype hemangioblastoma is characterized by being prepared from a DNA methyltransferase inhibitor. Through the DNA methyltransferase inhibitor, demethylation treatment can be conducted on genetic imprinting subtype hemangioblastoma patients and geneticimprinting subtype hemangioblastoma high-risk populations, so that VHL mRNA is re-expressed, and excellent treatment and prevention effects are achieved.

Description

technical field [0001] The invention relates to a drug for treating tumors, in particular to a drug for treating gene imprinted subtype hemangioblastoma. Background technique [0002] Von Hippel-Lindau (VHL) disease (OMIM 193300) is an autosomal dominant syndrome with the potential to develop a variety of benign and malignant neoplasms in various organ systems. Its inheritance results from germline mutations in the chromosomally located VHL gene and exhibits significant phenotypic variability, age-dependent penetrance, and interfamilial variation. Tumors characteristic of VHL include: central nervous system (CNS) and retinal hemangioblastomas (HBs), clear cell renal carcinoma, neuroendocrine tumors, pancreatic cysts, pheochromocytoma, etc. Most patients with VHL will be infected with CNS-HBs, with an incidence ranging from 34.3% to 72%. [0003] VHL disease occurs in all ethnic groups around the world. Both sexes are equally affected, with a prevalence rate of 1:30,000 to...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/706A61P35/00
CPCA61K31/706A61P35/00A61K2300/00
Inventor 马德选王莹
Owner AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap